MA
CLBT icon

Mutual Advisors’s Cellebrite CLBT Stock Holding History

Mutual Advisors’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,408
Closed -$205K – 1085
2024
Q3 		$205K Buy
+11,408
New +$169K 0.01% 1039

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

Mutual Advisors's CLBT Position: Q4 2024 in Review

Mutual Advisors sold out of Cellebrite (CLBT) in Q4 2024, closing a stake of 11,408 shares — an estimated $205K sold.

Mutual Advisors first reported a position in CLBT in Q3 2024 and held it in 1 quarter. The position peaked at $205K in Q3 2024. 191 funds tracked by Wall St. Rank hold CLBT as of Q4 2024.

  • Mutual Advisors reported no remaining Cellebrite position as of Q4 2024 after selling out during the quarter.
  • Mutual Advisors sold 11,408 Cellebrite shares in Q4 2024, an estimated $205K.
  • Mutual Advisors first reported a position in Cellebrite in Q3 2024 and held it in 1 quarter.
  • Mutual Advisors's Cellebrite position peaked at $205K in Q3 2024.
  • 191 funds tracked by Wall St. Rank held Cellebrite as of Q4 2024.

Based on Mutual Advisors's 13F filing for Q4 2024, filed 17 Jan 2025.